Looks like there are no answers to the hot potato question of earlier. How will Oncolix's market absorb the 126,000,000 shs being registered for sale pending the S-1 effective date? Oncolix's market is illiquid. The P1 study will not begin anytime soon, I doubt before Q2 2018 Theres limited capital So what catalyst will eat through all those shares?? Hopefully the answer doesnt lie in fluff PRs... Open to any reasonable ideas